233 related articles for article (PubMed ID: 21985916)
1. Pharmacokinetics, tissue distribution, excretion, and antiviral activity of pegylated recombinant human consensus interferon-α variant in monkeys, rats and guinea pigs.
Cai Y; Zhang Z; Fan K; Zhang J; Shen W; Li M; Si D; Luo H; Zeng Y; Fu P; Liu C
Regul Pept; 2012 Jan; 173(1-3):74-81. PubMed ID: 21985916
[TBL] [Abstract][Full Text] [Related]
2. A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjects.
Zheng L; Li MP; Gou ZP; Wang Y; Xu N; Cai YM; Luo H
Br J Clin Pharmacol; 2015 Apr; 79(4):650-9. PubMed ID: 25297637
[TBL] [Abstract][Full Text] [Related]
3. Long-acting interferon-alpha 2a modified with a trimer-structured polyethylene glycol: preparation, in vitro bioactivity, in vivo stability and pharmacokinetics.
Jo YW; Youn YS; Lee SH; Kim BM; Kang SH; Yoo M; Choi EC; Lee KC
Int J Pharm; 2006 Feb; 309(1-2):87-93. PubMed ID: 16406701
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the absolute bioavailability of pegylated interferon alfa-2a after subcutaneous administration to healthy male volunteers: an open-label, randomized, parallel-group study.
Brennan BJ; Xu ZX; Grippo JF
Clin Ther; 2012 Sep; 34(9):1883-91. PubMed ID: 22858176
[TBL] [Abstract][Full Text] [Related]
5. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD).
Reddy KR
Semin Liver Dis; 2004; 24 Suppl 2():33-8. PubMed ID: 15346244
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys.
Osborn BL; Olsen HS; Nardelli B; Murray JH; Zhou JX; Garcia A; Moody G; Zaritskaya LS; Sung C
J Pharmacol Exp Ther; 2002 Nov; 303(2):540-8. PubMed ID: 12388634
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic properties of a 40 kDa branched polyethylene glycol-modified form of consensus interferon-alpha (PEG-CIFN) in rhesus monkeys.
Du Y; Tian H; Gao XD; Yao WB
Biopharm Drug Dispos; 2008 Nov; 29(8):481-4. PubMed ID: 18985796
[TBL] [Abstract][Full Text] [Related]
8. Comparative effects of interferon alpha-2b and pegylated interferon alpha-2b on menstrual cycles and ovarian hormones in cynomolgus monkeys.
Enright BP; Compton DR; Collins N; Davis T; McIntyre BS
Birth Defects Res B Dev Reprod Toxicol; 2009 Feb; 86(1):29-39. PubMed ID: 19243028
[TBL] [Abstract][Full Text] [Related]
9. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity.
Pepinsky RB; LePage DJ; Gill A; Chakraborty A; Vaidyanathan S; Green M; Baker DP; Whalley E; Hochman PS; Martin P
J Pharmacol Exp Ther; 2001 Jun; 297(3):1059-66. PubMed ID: 11356929
[TBL] [Abstract][Full Text] [Related]
10. Comparative Pharmacokinetics, Tissue Distribution, Excretion of Recombinant Liver-Targeting Interferon with IFN α2b Administered Intramuscular in Rats.
Wang J; Lu X; Jin X; Zeng W; Zhu J
Curr Pharm Biotechnol; 2015; 16(10):911-9. PubMed ID: 26278706
[TBL] [Abstract][Full Text] [Related]
11. Site-Specific Transglutaminase-Mediated Conjugation of Interferon α-2b at Glutamine or Lysine Residues.
Spolaore B; Raboni S; Satwekar AA; Grigoletto A; Mero A; Montagner IM; Rosato A; Pasut G; Fontana A
Bioconjug Chem; 2016 Nov; 27(11):2695-2706. PubMed ID: 27731976
[TBL] [Abstract][Full Text] [Related]
12. N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.
Baker DP; Lin EY; Lin K; Pellegrini M; Petter RC; Chen LL; Arduini RM; Brickelmaier M; Wen D; Hess DM; Chen L; Grant D; Whitty A; Gill A; Lindner DJ; Pepinsky RB
Bioconjug Chem; 2006; 17(1):179-88. PubMed ID: 16417267
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.
García-García I; González-Delgado CA; Valenzuela-Silva CM; Díaz-Machado A; Cruz-Díaz M; Nodarse-Cuní H; Pérez-Pérez O; Bermúdez-Badell CH; Ferrero-Bibilonia J; Páez-Meireles R; Bello-Rivero I; Castro-Odio FR; López-Saura PA;
BMC Pharmacol; 2010 Nov; 10():15. PubMed ID: 21092287
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin.
Asahina Y; Izumi N; Umeda N; Hosokawa T; Ueda K; Doi F; Tsuchiya K; Nakanishi H; Matsunaga K; Kitamura T; Kurosaki M; Uchihara M; Higaki M; Miyake S
J Viral Hepat; 2007 Jun; 14(6):396-403. PubMed ID: 17501760
[TBL] [Abstract][Full Text] [Related]
15. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
[TBL] [Abstract][Full Text] [Related]
16. A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation.
Rosendahl MS; Doherty DH; Smith DJ; Carlson SJ; Chlipala EA; Cox GN
Bioconjug Chem; 2005; 16(1):200-7. PubMed ID: 15656592
[TBL] [Abstract][Full Text] [Related]
17. Structural and biologic characterization of pegylated recombinant IFN-alpha2b.
Grace M; Youngster S; Gitlin G; Sydor W; Xie L; Westreich L; Jacobs S; Brassard D; Bausch J; Bordens R
J Interferon Cytokine Res; 2001 Dec; 21(12):1103-15. PubMed ID: 11798469
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of pegylated interferons: what is misleading?
Caliceti P
Dig Liver Dis; 2004 Nov; 36 Suppl 3():S334-9. PubMed ID: 15645663
[TBL] [Abstract][Full Text] [Related]
19. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
Bell SJ; Fam CM; Chlipala EA; Carlson SJ; Lee JI; Rosendahl MS; Doherty DH; Cox GN
Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402
[TBL] [Abstract][Full Text] [Related]
20. An Evaluation of Optimal PEGylation Strategies for Maximizing the Lymphatic Exposure and Antiviral Activity of Interferon after Subcutaneous Administration.
Chan LJ; Feeney OM; Leong NJ; McLeod VM; Porter CJH; Williams CC; Kaminskas LM
Biomacromolecules; 2017 Sep; 18(9):2866-2875. PubMed ID: 28731677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
